GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lipocine Inc (STU:2VT0) » Definitions » Debt-to-Revenue

Lipocine (STU:2VT0) Debt-to-Revenue : 0.00 (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Lipocine Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Lipocine's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.00 Mil. Lipocine's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.00 Mil. Lipocine's annualized Revenue for the quarter that ended in Dec. 2023 was €0.79 Mil. Lipocine's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 0.00.


Lipocine Debt-to-Revenue Historical Data

The historical data trend for Lipocine's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lipocine Debt-to-Revenue Chart

Lipocine Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 43.17 N/A 0.14 - N/A

Lipocine Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A - N/A N/A -

Competitive Comparison of Lipocine's Debt-to-Revenue

For the Biotechnology subindustry, Lipocine's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lipocine's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lipocine's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Lipocine's Debt-to-Revenue falls into.



Lipocine Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Lipocine's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0 + 0) / -2.614
=0.00

Lipocine's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2023) Revenue data.


Lipocine Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Lipocine's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Lipocine (STU:2VT0) Business Description

Traded in Other Exchanges
Address
675 Arapeen Drive, Suite 202, Salt Lake City, UT, USA, 84108
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107.

Lipocine (STU:2VT0) Headlines

No Headlines